[1] The national institute of neurological disorders and stroke rt-PA stroke study group.Tissue plasminogen activator for acute ischemic stroke[J].N Engl J Med,1995,333(24):1581-1587.
[2] Hacke W,Kaste M,Bluhmki E,et al.Thrombolysis with Alteplase 3 to 4.5 hours after acute ischemic stroke[J].N Engl J Med,2008,359(36):1317-1329.
[3] IST-3 collaborative group,Sandercock P,Wardlaw JM,et al.The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acutre ischaemic stroke trial[IST-3]:a randomized controlled trial[J].Lancet 2012,379(9834):2352-2363.
[4] Hacke W,Kaste M,Fieschi C,et al.randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenousalteplase in acute ischaemic stroke(ECASS Ⅱ).Second European-Australasian acute stroke study investigators[J].Lancet,1998,352(9136):1245-1251.
[5] Heuschmann PU,Berger K,Misselwitz B,et al.Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality:the German stroke registers study group[J].Stroke,2003,34(5):1106-1113.
[6] Wang Y,Wu D,Zhao X et al.Hospital resources forurokinase/recombinant tissue-type plasminogen activator therapy for acute stroke in Beijing[J].Surg Neurol,2009,72(Suppl 1):S2-S7.
[7] Loh PK,Sharma VK.Intravenous thrombolysis with low-dose recombinant tissue plasminogen activator in acute ischemic stroke[J].Stroke,2010,41(8):e164.
[8] Yamaguchi T,Mori E,Minematsu K,et al.Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset:Japan alteplase clinical trial(J-ACT)[J].Stroke,2006,37(7):1810-1815.
[9] Mori E,Minematsu K,Nakagawara J,et al.Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion.Japan alteplase clinical trial Ⅱ(J ACT Ⅱ)[J].Stroke,2010,41(3):461-465.
[10] Nakagawara J,Minematsu K,Okada Y,et al.Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice:the Japan post-marketing alteplase registration study(J-MArS)[J].Stroke,2010,41(9):1984-1989.
[11] Chao AC,Hsu HY,Chung CP,et al.Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients:the Taiwan thrombolytic therapy for acute ischemic stroke(TTT-AIS)study[J].Stroke,2010,41(5):885-890.
[12] Sharma VK,Tsivgoulis G,Tan JH,et al.Feasibility and safety of intravenous thrombolysis in multiethnic Asian stroke patients in Singapore[J].J Stroke Cerebrovasc Dis,2010,19(6):424-430.
[13] Zhou XY,Wang SS,Collins ML,et al.Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke[J].J Clin Neurosci 2010,17(8):988-992
[14] Nguyen TH,Truong AL,Ngo MB,et al.Patients with thrombolysed stroke in Vietnam have an excellent outcome:results from the Vietnam Thrombolysis registry[J].Eur J Neurol,201017(9):1188-1192.
[15] Hsu YC,Sung SF,Ong CT,et al.Intravenous thrombolytic therapy for acute ischemic stroke:the experience of a community hospital[J].Acta Neurol Taiwan,2009,18(1):14-20.
[16] Kim SK,Lee SY,Bae HJ,et al.Pre-hospital notification reduced the door-to-needle time for iv t-PA in acute ischaemic strok[J].Eur J Neurol,2009,16(12):1331-1335.
[17] Dharmasaroja PA,Dharmasaroja P,Muengtaweepongsa S.Outcomes of Thai patients with acute ischemic stroke after intravenous thrombolysis[J].J Neurol Sci,2011,300(1/2):74-77.
[18] Chen CH,Hsieh CY,Lai TB,et al.Optimal dose for stroke thrombolysis in Asians:low dose may have similar safety and efficacy as standard dose[J].J Thromb Haemost,2012,10(7):1270-1275.
[19] 徐有恒.生理止血机制[M]//周衍椒,张镜如.生理学.3版.北京:人民卫生出版社,1994:83-88.
[20] Meierhenricha r,Carlssona J,Seifriedb E,et al.Effect of reteplase on hemostasis variables:analysis of fibrin specifity,relation to bleeding complications and coronary patency[J].Int J Cardiol,1998,65(1):57-63.